- Home
- MNOV vs ASRT Comparison
MNOV vs ASRT Comparison
Compare MNOV & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MNOV | ASRT |
|---|---|---|
| Founded | 2000 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.7M | 75.1M |
| IPO Year | 2005 | 1997 |
Fundamental Metrics
Financial Performance| Metric | MNOV | ASRT |
|---|---|---|
| Price | $1.32 | $0.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $7.00 | $3.00 |
| AVG Volume (30 Days) | 92.7K | ★ 307.1K |
| Earning Date | 11-12-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $257,917.00 | ★ $137,354,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 9.22 |
| 52 Week Low | $1.13 | $0.51 |
| 52 Week High | $2.20 | $1.01 |
Technical Indicators
Market Signals| Indicator | MNOV | ASRT |
|---|---|---|
| Relative Strength Index (RSI) | 35.74 | 33.71 |
| Support Level | $1.48 | $0.70 |
| Resistance Level | $1.51 | $0.75 |
| Average True Range (ATR) | 0.05 | 0.04 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 0.00 | 20.97 |
Price Performance
Historical ComparisonAbout MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's strategies are to focus its developing activities on therapeutics for neurological disorders and fibrotic diseases.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.